Specialty Chemicals DEALTRACKER

Who's buying, why they're buying, and what it means for owners and executives.



What is a DealTracker?

Our DealTrackers give business leaders and owners a clear view of M&A activity in their sector. They are designed to help answer critical strategic questions such as:

- Who are the key deal-makers, and what do they value?
- What is the current market value of businesses like mine?
- Is now the right time to diversify, invest, or divest?

This **Specialty Chemicals DealTracker** draws on:

- Proprietary deal data, with a focus on the often overlooked lower-mid market.
- Interviews with M&A decision-makers at mid-cap specialty chemicals businesses.
- Conversations with private equity principals investing in the sector.

Result:

A practical, executive-level snapshot of buyer behaviour, market valuations, and emerging trends – insights we rely on when advising our specialty chemicals clients.

	Section	What it is	Page
1	Activity, Valuation, and Trends	The specialty chemicals space is defined by companies that focus on chemistry-driven portfolios, delivering material products through R&D-led advancements. This section highlights a selection of deal flow and valuation metrics combined with insights on strategies from M&A and investor decision-makers in the specialty chemicals sector.	4-7
2	Strategic Buyer Landscape	Analytics on the cohort of ~600 strategic trade buyers we have identified as likely interested in acquiring in the specialty chemicals sector. Based on a combination of publicly available data and interviews with M&A decision-makers (typically, CEOs and strategic executives).	8-11
3	Financial Investor Landscape	Analytics on the cohort of ~250 private equity and family office investors we have identified as likely interested in investing in the specialty chemicals sector. Based on a combination of publicly available data and interviews with principals.	12-15
4	About the Authors	An overview of the CCD Partners team, how we collect the data and insights necessary to produce this DealTracker, and our other similar publications.	16-17





Acquirers using M&A to stay ahead of industry trends

Three big trends we're hearing

Mid-sized companies dominate green chemistry

Petrochemical closures in Europe have resulted in small/midsized companies leading growth and innovation in green chemistry.

Large players' appetites for M&A increasing

Larger specialty chemicals businesses are shifting away from in-house innovation, favouring inorganic growth through acquisitions.

High-value end markets

Businesses serving digital and electronics end markets have seen strong growth and are in high demand.



Our dedicated research team has discussed M&A strategies and intentions with 120+ decision-makers in the space

Executives looking to M&A to help achieve their strategic growth ambitions



"I'm only interested in differentiated technologies that fit with my existing portfolio"

Head of Strategy \$3bn+ revenue specialty chemicals co.



"We want a company at the leading edge of high-tech, sustainable technologies"

Head of M&A \$4bn+ revenue specialty chemicals co.



"...we need to acquire a company that fits with our existing market and resin portfolio..."

Head of Strategy \$500m+ revenue resins manufacturer

Rising deal flow and multiples

Momentum is building into H1 2026

The key question: sustained rebound or temporary surge?

Specialty chemicals deal flow maintains momentum in 2025

Our discussions point to ongoing momentum in the specialty chemicals deal flow throughout 2025 and into 2026. This follows indications that, as global economic conditions improve, supply chains are rebalancing, and private investors are putting more capital to work.




Chart: Specialty Chemicals deals recorded per quarter per region. Source: CCD estimates, proprietary database, and public data


Valuation EBITDA multiples see sector-specific variation



High multiples - high-tech end markets such as the aerospace, medical, and electronics industries

Mid-range multiples – businesses in the polymers, CASE, and food/nutrition sectors

Low multiples are seen in commoditised and lowvalue product offerings



Who are the most active buyers

The companies buying the most specialty chemicals businesses

Historic no. of acquisitions per year

(average last 4 years)



Sika has acquired 11 specialty chemical firms globally over the last four years, expanding product offerings and regional presence. Results: strengthened market share, boosted portfolio diversity, margin leverage

Solenis



ARKEMA

Givaudan



3

Top buyers contribute to valuation benchmarks, revealing consolidation trends, and highlighting strategic themes



SK Capital executed 8 acquisitions, targeting specialty chemicals carve-outs. Results: expanded portfolio, platform roll-ups, consolidation strength, strong PE sponsor positioning








1

Chart: Top buyers in Specialty Chemicals, 2022 to present. Source: Buyer websites, proprietary database, and public data



615 Potential Trade Buyers

Analytics based on the profiles we have on over 600 strategic trade players: where they operate, what they sell, and what they want to buy

Strategic consolidators remain central to the specialty chemicals buyer landscape - yet often little detail is published on their M&A priorities. Real insight comes from direct conversations and long-term relationships.

Here's what we found:

>60 mid-large specialty chemicals conversations (and ~600 profiled) this year

Cross-border ambitions

Many trade players are looking beyond their home markets to fill portfolio gaps and access higher-growth markets, making cross-border acquisitions an important part of M&A strategies.




Chart: Mid-large specialty chemicals businesses split by HQ region Source: CCD estimates, proprietary database, and public data

Portfolio enhancement

The portfolios of large specialty chemicals businesses can be highly diverse. Which targets constitute strategic, high-value, additions is not always clear from publicly available information. One of the key data points we record is what constitutes the 'ideal' acquisition.



Strategic M&A themes are often driven by size





Chart: Mid-large specialty chemicals businesses split by revenue / size data Source: CCD estimates, proprietary database, and public data

Ownership structure can drive priorities

The trade buyers come from a variety of ownership backgrounds, each bringing its own angle on M&A priorities



^{*}This is a category we record separately as subsidiaries often function independently in M&A

Strategic M&A priority themes

...we see cutting across most of the conversations we are having with decision-makers of mid-cap specialty chemicals businesses













Evonik - strategic transformation through M&A

Evonik is a global specialty chemicals leader that has transformed its portfolio from commodity-heavy to innovation-driven businesses through divestitures and targeted acquisitions





2017:

Divests majority of methacrylates BU, shifting away from commoditised chemicals

2018

Acquires Dr. Straetmans expanding personal care portfolio

2019:

Acquires PeroxyChem – adds specialty oxidants and environmental applications

2021:

Acquires Wilshire Technologies – strengthens pharma and lifesciences excipients

2022:

Acquires Schill+Seilacher's care chemicals unit and invests in sustainable animal nutrition

M&A Themes:

Geographic Expansion

Huber Silica aided expansion in North America & Asia; Porocel added sites in the US, Canada, Luxembourg, Singapore; PeroxyChem strengthened Evonik's U.S. footprint.

Specialty Segment Deepening

Acquisitions enhanced life sciences, nutrition, cosmetics, and healthcare, reducing reliance on cyclic industries and stabilising demand.

Technology and Innovation

3D-printing materials via Structured Polymers (2019) to broaden specialty polymer powders; eco-solutions and disinfection via PeroxyChem (H₂O₂/PAA).

Cultural and Operational Fit

M&A accelerated the transition to greener chemistries, low-VOC solutions, and circular economy initiatives, improving margins and investor appeal.

Source: Summarised CCD estimates and public information, including Evonik's website, trade journals, and press releases.



250 Potential Financial Buyers

Analytics based on the profiles we have on 250 financial investors: where they operate and their investment theses and preferences

Private equity and family offices are an important part of the buyer landscape, but their enthusiasm for specific deals is hard to predict, even with close monitoring of their investment theses and preferences.

The only reliable way is to test each opportunity with a wide group of investors - fortunately, PE screening processes are typically fast and efficient.

Nonetheless, some general themes did emerge from our discussions:


50+ private equity
conversations
(and ~250 profiled)
this year

Regional focus sharpening


Historically, a number of financial investors have looked to make investments across the Atlantic (in both directions).

This trend continues, but we have also noticed an increase in investors that more strongly prioritise focus in a specific local region.

Chart: Financial investors split by HQ region Source: CCD estimates, proprietary database, and public data



Proliferation of boutique investors



We have noticed an appreciable uptick in boutiques, family offices, and other smaller more entrepreneurial investors. Often originating from seasoned principals setting out on their own rather than relying on a well-known umbrella brand.

Such smaller, more agile investors, bring both advantages and challenges for sellers. In particular, lower-mid market sellers that may have been too small for a classic PE play are now more likely to attract viable financial investor options.

Chart: Financial investors split by scale and scope Source: CCD estimates, proprietary database, and public data

Private Equity FAQs

Below we have noted some of the most common questions we're asked by owners considering private equity options. The answers are a blend of our experience and views from "PE" professionals themselves.



Do PE firms have fixed investment terms?

The typical term range is 3–7 years, but it depends on the growth plan and specific circumstances. PE firms are increasingly flexible on timing, and this is often an attractive trait for sellers.



Do PE firms offer less as they don't benefit from synergies?

In our experience (in the lower-mid market) PE can often actually offer more than strategics. Particularly if a growth case can be made, typically using the target business as a platform for rapid expansion.



Can we engage trade buyers and PE at the same time?

For PE to be a viable option the business must meet certain criteria. Most of which can be prepared in advance. In which case, we typically recommend both tracks are pursued simultaneously.



Do owners typically stay after a PE acquisition?

In most cases, yes. PE firms often want the owners to remain involved to maintain continuity in management. To what extent and for how long will vary depending on the circumstances and negotiation.



What are the biggest drivers of valuation for PE?

Positioning the business as a platform for growth that only requires support and guidance on "how" to grow rather than "why" it will grow. This is the holy grail for many PE investors.

PE investment priority themes

...we see cutting across most of the conversations we are having with principals in PE firms interested in specialty chemicals.





Technical and Formulation Capabilities



Growth-Boosting M&A Pipeline



Differentiated and Diverse Offering



Demonstrable Scalability

Case Study

Royal Adhesives – M&A-boosted growth

Royal Adhesives was a diversified adhesives developer and manufacturer that has grown rapidly following an investment from Arsenal Capital in 2010, selling for \$1.6bn in 2017





2010-2015: Acquires 8 specialty adhesives businesses including Chemical Innovations

2015:

Bought by PE firm, American Securities

2016:

Acquires Bacon Adhesives

2017 \$1.6bn

\$1.0

Investment Themes:

Adhesives

2010:

Arsenal Capital

acquires Royal

Geographic Expansion

Royal moved beyond a U.S. base with Chemque in Canada (2014) and the UKbased Chemical Innovations Limited (2015).

Differentiated and Diverse Offering

Acquisitions pushed Royal deeper into performance niches: Clifton Adhesives (aerospace); ADCO Global (construction); Chemical Innovations Ltd. (rubber-tometal bonding)

Demonstrable Scalability

Royal was used by Arsenal Capital as a buy-and-build platform—starting with Para-Chem (2010) and completing eight add-ons before the 2015 sale to American Securities.

Technology and Formulation

Acquired by H.B.

Fuller for \$1.6bn

2017:

Royal added complementary chemistries and cure systems to enable cross-sell and custom solutions.

Source: Summarised CCD estimates and public info, including Arsenal and H.B. Fuller's websites, trade journals, and press releases.

About the Authors

CCD Partners is a people business. We pair senior ex-industry advisors who know the market personally with an execution team that knows how to deliver deals – all backed by a market engagement team out in the world collecting data and insights not available online.





Tim Evans

Specialty Chemicals Execution Lead

- 25+ years' transactional experience
- Chemicals M&A execution specialist with experience in specialty chemicals, life sciences, and distribution





Matt Dixon

Managing Partner

- 18+ years' transactional experience
- Co-founded CCD Partners and is Head of M&A







Peter Dixon

Chairman

- 40+ years' industry and transactional experience
- 100+ chemistry-driven M&A clients






Matthew Wise

Head of Data and Market Engagement

- Specialist at acquisition searches, landscape screening, and market research
- Oversees market engagement and data gathering team





Other Publications

available at ccdpartners.com or via email to contact@ccdpartners.com

WatchLists

Reports on lower-mid market companies in specific sub-sectors

Pre-Clinical CROs



CPHI Start-Ups



Performance Additives



Adhesive Formulators



Chemical Distributors



DealTrackers

Reports on deals and mid-cap acquirors by headline sector

Chemical Distribution



Specialty Chemicals



Pharma-Services



Green Chemistries



PlayBooks

Your M&A playbook. Built for you.

Divestments







"A bespoke executive planning tool powered by the full WatchList and DealTracker intelligence – applied to a client's specific circumstances."

Matt Dixon Managing Partner

